SCHEMBL6447567

SCHEMBL6447567

Cc1ccc(-c2ccccc2OC(=O)O)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.55
L3MBTL1 Q9Y468 3/20 0.55
TDP1 Q9NUW8 2/20 0.55
MAPK1 P28482 1/20 0.55
ALDH1A1 P00352 2/20 0.49
HTT P42858 1/20 0.49
FABP3 P05413 2/20 0.45
FABP7 O15540 1/20 0.45
FABP5 Q01469 1/20 0.45
SYK P43405 1/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
RAB9A P51151 2/20 0.45
GLA P06280 1/20 0.45
PAX8 Q06710 1/20 0.45
PTGDR2 Q9Y5Y4 1/20 0.43
KDM4E B2RXH2 3/20 0.42
CYP1A2 P05177 2/20 0.41
MAPT P10636 2/20 0.41
CYP2C9 P11712 2/20 0.41
CYP2C19 P33261 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8986479 0.87 FABP3 (0.53) LMNAL3MBTL1TDP1MAPK1ALDH1A1
SCHEMBL236823 0.87 FABP3 (0.53) LMNAL3MBTL1TDP1MAPK1ALDH1A1
SCHEMBL1639323 0.87 FABP3 (0.56) LMNAL3MBTL1TDP1MAPK1ALDH1A1
SCHEMBL30563023 0.87 FABP3 (0.56) LMNAL3MBTL1TDP1MAPK1ALDH1A1
SCHEMBL867780 0.86 MAOB (0.52) LMNAL3MBTL1TDP1MAPK1ALDH1A1
SCHEMBL709954 0.86 LMNA (0.51) LMNAL3MBTL1TDP1MAPK1ALDH1A1
SCHEMBL27678114 0.84 L3MBTL1 (0.43) LMNAL3MBTL1TDP1MAPK1ALDH1A1
SCHEMBL7647143 0.84 LMNA (0.50) LMNAL3MBTL1TDP1MAPK1ALDH1A1
SCHEMBL8059091 0.84 FABP3 (0.46) LMNAL3MBTL1TDP1ALDH1A1FABP3
SCHEMBL7024866 0.84 FFAR4 (0.47) LMNAL3MBTL1TDP1MAPK1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1169289-B1 METHOD FOR PRODUCING DERIVATIVES OF BIPHENYL-2-CARBOXYLIC ACID BOEHRINGER INGELHEIM PHARMA (DE) 2003-10-29 EP claimed
EP-1169289-A1 METHOD FOR PRODUCING DERIVATIVES OF BIPHENYL-2-CARBOXYLIC ACID Boehringer Ingelheim Pharma KG (DE) 2002-01-09 EP claimed
WO-2000051961-A1 METHOD FOR PRODUCING DERIVATIVES OF BIPHENYL-2-CARBOXYLIC ACID BOEHRINGER INGELHEIM PHARMA KG (DE) 2000-09-08 WO claimed
US-9012676-B2 Processes for producing aryl carbamates, isocynates and polyureas using diaryl carbonate GREAT EASTERN RESINS INDUSTRIAL CO., LTD. (CN) 2015-04-21 US disclosed
US-20130079542-A1 PROCESSES FOR PRODUCING ARYL CARBAMATES, ISOCYNATES AND POLYUREAS USING DIARYL CARBONATE NATIONAL CHUNG HSING UNIVERSITY (TW) 2013-03-28 US disclosed
EP-1210322-B1 METHOD FOR CARRYING OUT THE SIDE CHAIN BROMINATION OF 4-METHYL BIPHENYL DERIVATIVES SUBSTITUTED AT THE 2'-POSITION BOEHRINGER INGELHEIM PHARMA (DE) 2005-02-09 EP disclosed
EP-1169289-B1 METHOD FOR PRODUCING DERIVATIVES OF BIPHENYL-2-CARBOXYLIC ACID BOEHRINGER INGELHEIM PHARMA (DE) 2003-10-29 EP disclosed
WO-2003066565-A1 DEUTERATED BIPHENYL DERIVATIVES TURICUM DRUG DEVELOPMENT AG (CH) 2003-08-14 WO disclosed
WO-2003066626-A1 DEUTERATED BIPHENYL-SUBSTITUTED BENZIMIDAZOLES AND MEDICAMENT CONTAINING SAID COMPOUNDS FOR THE TREATMENT OF HYPERTONIA TURICUM DRUG DEVELOPMENT AG (CH) 2003-08-14 WO disclosed
EP-1102738-B1 METHOD FOR THE ACIDIC OR ALKALINE SAPONIFICATION OF BIPHENYL NITRILES LEHMANN BERND DR (DE) 2002-12-04 EP disclosed
EP-1169289-A1 METHOD FOR PRODUCING DERIVATIVES OF BIPHENYL-2-CARBOXYLIC ACID Boehringer Ingelheim Pharma KG (DE) 2002-01-09 EP disclosed
EP-1102738-A1 METHOD FOR THE ACIDIC OR ALKALINE SAPONIFICATION OF BIPHENYL NITRILES Great Lakes Chemical Konstanz GmbH (DE) 2001-05-30 EP disclosed
US-6143917-A FROM A DIARYL CARBONATE AND AN AMINE COMPOUND HAVING AT LEAST ONE HYDROGEN ATOM LOCATED AT AN N-POSITION UNDER MODERATE CONDITIONS AT A HIGH REACTION RATE WITH A HIGH SELECTIVITY AND WITH A HIGH YIELD UBE INDUSTRIES, LTD. (JP) 2000-11-07 US disclosed
WO-2000051961-A1 METHOD FOR PRODUCING DERIVATIVES OF BIPHENYL-2-CARBOXYLIC ACID BOEHRINGER INGELHEIM PHARMA KG (DE) 2000-09-08 WO disclosed
WO-2000003964-A1 METHOD FOR THE ACIDIC OR ALKALINE SAPONIFICATION OF BIPHENYL NITRILES GREAT LAKES CHEMICAL KONSTANZ GMBH (DE) 2000-01-27 WO disclosed
EP-0902014-A1 PROCESS FOR PRODUCING ARYL CARBAMATES UBE INDUSTRIES LIMITED (JP) 1999-03-17 EP disclosed
WO-1991013063-A1 NEW BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING THEM AND THEIR PHARMACEUTICAL USE SCHERING AKTIENGESELLSCHAFT BERLIN UND BERGKAMEN (DE) 1991-09-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130079542-A1 PROCESSES FOR PRODUCING ARYL CARBAMATES, ISOCYNATES AND POLYUREAS USING DIARYL CARBONATE UROD, DDC, TST LMNA 1353/4885L3MBTL1 4521/4885TDP1 2593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.